EARLY CONFIRMED SPEAKERS

 

We arwe working hard to create the best agenda yet, and to make sure we invite the most excellent speakers to speak at the congress in 2020.

We have already confirmed over 80 out of 350+ speakers, and the list is ever growing.

 

  • Dr Ofer Levy, Professor of Pediatrics, Precision Vaccines Program, Boston Children's Hospital, Harvard Medical School

  • Dr Julia Spencer, Associate Vice President, Global Vaccine Public Policy, Partnerships, & Government Affairs, Merck

  • Dr Leonard Friedland, VP, Scientific Affairs and Public Health, GSK

  • Dr Matt Hepburn, Former  Program Manager, DARPA

  • Dr Olivera Finn, Distinguished Professor, Department of Immunology, University of Pittsburgh School of Medicine

  • Dr Fred Ramsdell, CSO, Parker Institute for Cancer Immunotherapy 

  • Dr Karolina Palucka, Professor, Principal Investigator, Distinguished Professor, Department of Immunology, The Jackson Laboratory

  • Dr Elizabeth Mittendorf, Associate Professor for Department of Surgical Oncology, Dana-Farber / Brigham and Women's Cancer Center

  • Dr Emmett Schmidt, Associate Vice President, Merck

  • Dr Benjamin Vincent, Assistant Professor, Division of Hematology/ Oncology, UNC Lineberger Comprehensive Cancer Center

  • Dr Adrian Wildfire, Scientific Director - Infectious Diseases & Human Challenge Unit, SGS

  • Dr Cynthia Dukes, VP, Scientific and Clinical Services and Head of Vaccine Center of Excellence, ICON

  • Dr Darin Seehafer, Sr. Clinical Scientist, PRA

  • Dr Mark Alderson, Director - Pneumococcal Vaccine Project Vaccine Development Global Program, Path

  • Dr Mary Marovich, Director of Vaccine Research Program, NIH

  • Dr Louis Picker, Managing Director, Oregon Health & Science University

  • Dr Daria Hazuda, CSO & Vice President of Infectious Diseases Discovery, Merck

  • Dr Philip Krause, Deputy directoer, CBER, FDA

  • Dr Patrick Emmet Duffy, Chief, Laboratory of Malaria Immunology and Vaccinology, NIH

  • Dr Will Singleterry, Director, Scientific Collaborations, IsoPlexis 

  • Dr Bibhash Mukhopadhyay, Principal, New Enterprise Associates

  • Dr Tim Cooke, Senior Vice President, Commercial Business, Ology Bioservices & NVPO

  • Dr Stephen Hoffman, CEO, Sanaria

  • Dr Malte Meppens, Head of Drug Product Development, GSK

  • Dr Mario Roederer, Chief Of Immuno Technology, NIH

  • Dr Nikolai Petrovsky, Chairman, Flinders U

  • Dr Stephen Johnston, Director, Biodesign Institute, Arizona State University

  • Dr Jean-Jacques Muyembe-Tamfum, Director-General, National Institute for Biomedical Research, Democratic Republic of the Congo (DRC)

  • Dr John Markels, President, Merck

  • Dr Saad Omer, Professor Global Health, Epidemiology and Pediatrics, Emory Vaccine Center, Yale University 

  • Dr Inci Yildirim, Associate Professor, Emory University 

  • Dr Larry Wolfraim, Program Officer, Biodefense Vaccines and other Biological Products Development Section, Office of Biodefense, Research Resources, and Translational Research

  • Dr Peter Hotez, Dean, Professor, Co-Head of Pediatric Tropical Medicine Baylor College of Medicine & Co-Director, Texas Children’s Hospital Center for Vaccine Development

  • Dr Ann Ginberg, Senior Technical Advisor, IAVI

  • Dr Kathryn Edwards, Professor of Pediatrics, Vanderbilt 

  • Dr Ilse Dieussaert, Director and Head of Maternal Immunization Vaccine Development, GSK

  • Dr Barney Graham, Deputy Director, VRC, NIAID, NIH

  • Dr Brian Abramson, Attorney and Treatise Author

  • Dr Bruno Speder, Head Clinical Refulatory Affairs, Consultancy, SGS

  • Dr Lynlee Burton, Senior Director, Therapeutic Expertise - Vaccines, PRA

  • Dr James Cummings, President, ICON Government and Public Health Solutions, ICON

  • Dr Cynthia Derdeyn, Professor, Emory Vaccine Center

  • Dr Walter Straus, Associate Vice President, Therapeutic Area Head, Clinical Safety And Risk Management, Merck Research Laboratories

  • Dr Scott Halstead, Adjunct Professor, Department Of Preventive Medicine And Biometrics, Uniformed Services University of Health Services

  • Dr Daniel Salmon, Director, Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health 

  • Dr Raina MacIntyre, Principal Research Fellow and Professor of Global Biosecurity, University of New South Wales 

  • Dr Yenlik Zheteyeva, Director, Clinical Safety and Risk Management, Merck Research Laboratories

  • Dr Angus Thomson, Head, Vaccine Confidence and Coverage, Global Public Affairs, Sanofi Pasteur

  • Dr Bob Chen, Scientific Director, Brighton Collaboration

  • Dr Anna Durbin, Professor, International Health, Global Disease Epidemiology and Control, Johns Hopkins Bloomberg School of Public Health

  • Dr William McGillian, Associate Director Supply Chain Management, Product Handling and Technology, Merck

  • Dr Jerald Sadoff, Senior Advisor Vaccine Development, Janssen

  • Dr Jon Henrich, Associate Vice President and Segment Head, Sanofi

  • Dr John Mascola, Director-Vaccine Research Center, NIH

  • Dr Maura Kibbey, Senior Scientific Fellow, Education & Training

  • Global Biologics, USP

  • Dr Ashley Kalinauskas, Founder & CEO, Torigen Pharmaceuticals

  • Dr Patricia Lawman, CEO, Morphogenesis 

  • Dr GS Reddy, SVP, Brilliant Bio Pharma Private Limited, Hyderabad, India

  • Dr Cyril Gay, Senior National Program Leader, Office of National Programs, USDA

  • Dr Douglas Thamm, Professor of Oncology, Director of Clinical Research, Colorado State University

  • Dr Derek O'Hagan, Global Head of Discovery Support and New Technology, GSK Vaccines 

  • Dr Peter Palese, Horace W. Goldsmith Professor and Chair, Department of Microbiology, Professor, Icahn School of Medicine at Mount Sinai